Hospitals; urine drug screening to include testing for fentanyl.
HB2742 amends Virginia law governing hospital and nursing home licensure and operating standards, with its headline change requiring emergency departments to include fentanyl testing when they perform urine drug screening to help diagnose a patient’s condition. The bill also adds a new definition of “urine drug screening” in the hospital licensing statute and makes the fentanyl-testing requirement part of the Board of Health’s regulations for licensed hospitals. The act is effective January 1, 2026.
Although the bill is titled around fentanyl testing, it also carries forward and expands a long list of existing hospital and long-term care regulatory requirements in the licensing statute. Those provisions cover matters such as emergency department physician coverage, organ donation protocols, obstetrical transfer procedures, discharge planning for substance-abusing postpartum women, patient rights, neonatal care standards, nursing home vaccination requirements, sex offender registry notifications, visitation rights, liability insurance, psychiatric admission communications, emergency department security planning, air medical transport notice, temporary bed exemptions during emergencies, cannabis oil administration in nursing homes, substance use-related emergency discharge protocols, visitation during public health emergencies, access to intelligent personal assistants, parent access to minors’ health records, and smoke evacuation systems for surgeries.
The bill’s practical impact is to require hospitals with emergency departments to broaden toxicology screening to include fentanyl, which may improve detection of fentanyl exposure and inform treatment decisions in overdose and other acute-care situations. It also reinforces the regulatory authority of the Board of Health over hospital licensure and standards, while leaving most existing hospital and nursing facility obligations intact. Hospitals, emergency departments, and clinicians who order or interpret urine drug screens are the primary affected parties, along with patients whose care may be influenced by more complete toxicology results.
The overall sentiment reflected in the voting history was strongly favorable and noncontroversial. The bill advanced unanimously through a House subcommittee, the House Health and Human Services Committee, the full House, the Senate Education and Health Committee, and the full Senate, with no recorded dissenting votes. That pattern suggests broad bipartisan support for the fentanyl-testing requirement and the related health and safety provisions.
No major points of contention appear in the available record. The bill’s substance use and emergency department provisions could raise operational or cost concerns for hospitals, but no opposition was recorded in committee or floor votes. The absence of transcript discussion also suggests the measure was treated as a technical public-health and patient-safety update rather than a disputed policy change.
HB2742 amends Virginia Code §§ 32.1-123 and 32.1-127 to add fentanyl testing to urine drug screening in hospital emergency departments and to update the definition of urine drug screening. It also revises the hospital licensing regulations section to include a new requirement that emergency departments test for fentanyl when urine screening is used to assist in diagnosis, effective January 1, 2026. The bill leaves in place and restates a broad set of existing licensure standards for hospitals, nursing homes, and certified nursing facilities, affecting the Board of Health, licensed facilities, clinicians, and patients.
The bill appears to have received very strong support throughout the legislative process. It passed subcommittee, full committee, the House, and the Senate unanimously, with recorded votes of 8-0, 21-0, 97-0, 99-0, 15-0, 39-0, and 40-0. No committee transcript objections are available, and the voting history indicates a consensus that the measure serves a public-health and patient-safety purpose.
No notable opposition is reflected in the available materials. The most likely practical concerns would be implementation costs, laboratory workflow changes, and compliance burdens for emergency departments that currently do not routinely include fentanyl in urine drug screens, but none of these concerns appear in the recorded votes or transcripts. The measure’s broad health-facility regulatory language is extensive, but the only clearly new policy change highlighted in the bill title and context is the fentanyl-testing requirement.